CNBX Pharmaceuticals Inc. (CNBX)

Market Cap	280.00K
Revenue (ttm)	40.64K
Net Income (ttm)	-551.03K
Shares Out	31.11M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,000
Average Volume	90,433
Open	0.0100
Previous Close	0.0100
Day's Range	0.0100 - 0.0100
52-Week Range	0.0050 - 0.0200
Beta	0.79
RSI	57.80
Earnings Date	Jan 13, 2025

About CNBX Pharmaceuticals

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast canc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: CNBX

Financial Performance

In 2024, CNBX Pharmaceuticals's revenue was $130,074, a decrease of -68.29% compared to the previous year's $410,165. Losses were -$695,198, -81.26% less than in 2023.